Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.60 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DHCR7 | Q9UBM7 | 2/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.40 |
| ▸ | TUBB | P07437 | 2/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051413 | 0.83 | CA2 (0.64) | CA9CA2KDM4EGAAMAPT | |
| SCHEMBL3055295 | 0.81 | DHCR7 (0.58) | CA9CA2KDM4EDHCR7DRD2 | |
| SCHEMBL3057024 | 0.81 | CA9 (0.39) | CA9CA2KDM4EGAAMAPT | |
| SCHEMBL3050097 | 0.75 | CA9 (1.00) | CA9CA2KDM4EGAAMAPT | |
| SCHEMBL3051335 | 0.75 | POLB (0.45) | CA9CA2GAATUBB4ATUBB | |
| SCHEMBL3049007 | 0.73 | CA9 (0.86) | CA9CA2KDM4EGAAMAPT | |
| SCHEMBL3052491 | 0.73 | CA9 (0.60) | CA9CA2KDM4EGAAMAPT | |
| SCHEMBL3056180 | 0.71 | CA9 (0.72) | CA9CA2DRD2DRD1DRD5 | |
| SCHEMBL3052219 | 0.68 | CA9 (0.84) | CA9CA2KDM4EGAAMAPT | |
| SCHEMBL3051537 | 0.68 | MAOA (0.44) | CA9CA2KDM4EGAATUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | claimed |
| EP-2155192-B1 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LTD (GB) | 2016-09-28 | — | — | EP | disclosed |
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | CA9 1002/4885CA2 1077/4885KDM4E 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.